Skip to content
DataLookout
Menu

NCT07928661

Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in the Visceral Adiposity Index (VAI) from baseline to week 12
Timeframe: Baseline and week 12
Change in HOMA-IR from baseline to week 12
Timeframe: Baseline and week 12
Change in C-Peptide from baseline to week 12
Timeframe: Baseline and week 12
Change in Controlled Attenuation Parameter (CAP) from baseline to week 12
Timeframe: Baseline and week 12

Secondary (3)

Changes in HbA1c levels from baseline to week 12
Changes in fasting glucose levels from baseline to week 12
Changes in 2-hour postprandial glucose levels from baseline to week 12

Arms and interventions

Proliverenol Supplementation 1000 mg with standard Therapy of DMExperimental

Participants in this arm will receive Proliverenol supplementation at a dose of 1000 mg twice daily for duration 12 weeks and standard theraphy (rapid-acting insulin three times a day, basal insulin once a day, or metformin 500 mg three times a day, or sitagliptin 50 mg twice a day, or gliclazide MR 60 mg once a day)

Patients receive standard of care treatment onlyActive comparator

rapid-acting insulin three times daily, basal insulin once daily, or metformin 500 mg three times daily, or sitagliptin 50 mg twice daily, or gliclazide MR 60 mg once daily

Drugs: Proliverenol

Sites

1 site in 1 country

  • University of Sriwijaya PalembangPalembang, South Sumatera, Indonesia